Limits...
BRAFV600E mutation positive metastatic melanoma in a young woman treated with anti-BRAF/anti MEK combination: a case report

View Article: PubMed Central - HTML

AUTOMATICALLY GENERATED EXCERPT
Please rate it.

The recent Combi-v and Combi-d, phase III randomized trials, showed, respectively, an OS benefit with Dabrafenib/Trametinib combination versus Vemurafenib and an improvement in PFS and ORR with the same combination versus Dabrafenib alone, in BRAF V600E/K mutation positive metastatic or unresectable cutaneous melanoma... We report the case of a young patient with metastatic melanoma treated with antiBRAF/antiMEK combination... No comorbidities, no previous melanoma treatment... In May 2011 the patient reported a traumatic event which resulted in the removal of a mole localized in the right thigh... On January 2014, due to the worsening of the swelling and pain, which resulted in the patient becoming unable to maintain a sitting position, she underwent an ultrasound exam that displayed pathological lymph nodes... A CT/PET displayed conglobated pathological lymph nodes in right groin of around 10 cm; right iliac obturator lymph node of 6 cm and osteolytic lesion at sacroiliac articulation... In April 2014, after adequate screening, the patient began Dabrafenib/Trametinib combination under the Compassionate Use program... Just after one month of treatment she reported clinical benefit in terms of deambulation improvement and pain relief... Progressively the antiBRAF drug was reintroduced with no further interruption... The CT/PET performed after three and six month of treatment showed a good response to the therapy with a dimensional decrease and SUV reduction of more than 50% in all target lesions... Currently the patient is continuing the treatment; her ECOG PS is 0... She does not require any antalgic drugs... Our aim is obtain the maximum reduction to allow a surgical approach... Written informed consent was obtained from the patient for publication of this abstract.

No MeSH data available.


September 2014
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4315288&req=5

Figure 2: September 2014


BRAFV600E mutation positive metastatic melanoma in a young woman treated with anti-BRAF/anti MEK combination: a case report
September 2014
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4315288&req=5

Figure 2: September 2014

View Article: PubMed Central - HTML

AUTOMATICALLY GENERATED EXCERPT
Please rate it.

The recent Combi-v and Combi-d, phase III randomized trials, showed, respectively, an OS benefit with Dabrafenib/Trametinib combination versus Vemurafenib and an improvement in PFS and ORR with the same combination versus Dabrafenib alone, in BRAF V600E/K mutation positive metastatic or unresectable cutaneous melanoma... We report the case of a young patient with metastatic melanoma treated with antiBRAF/antiMEK combination... No comorbidities, no previous melanoma treatment... In May 2011 the patient reported a traumatic event which resulted in the removal of a mole localized in the right thigh... On January 2014, due to the worsening of the swelling and pain, which resulted in the patient becoming unable to maintain a sitting position, she underwent an ultrasound exam that displayed pathological lymph nodes... A CT/PET displayed conglobated pathological lymph nodes in right groin of around 10 cm; right iliac obturator lymph node of 6 cm and osteolytic lesion at sacroiliac articulation... In April 2014, after adequate screening, the patient began Dabrafenib/Trametinib combination under the Compassionate Use program... Just after one month of treatment she reported clinical benefit in terms of deambulation improvement and pain relief... Progressively the antiBRAF drug was reintroduced with no further interruption... The CT/PET performed after three and six month of treatment showed a good response to the therapy with a dimensional decrease and SUV reduction of more than 50% in all target lesions... Currently the patient is continuing the treatment; her ECOG PS is 0... She does not require any antalgic drugs... Our aim is obtain the maximum reduction to allow a surgical approach... Written informed consent was obtained from the patient for publication of this abstract.

No MeSH data available.